Pipeline & Programs

Learning about DNA Phenotyping

Nevakar Injectables’ business model focuses on repositioning and repurposing existing drugs to address unmet needs that are patient and health care system centric. Nevakar Injectables’ unique ideation and pipeline development process allows us to accelerate discovery, development and commercial launch.

We call this novel approach NuPharmingTM.

portfolio

Hospital Injectables

Hospital Injectables is an underserved market presenting significant patient and healthcare system value. Suboptimal products and delivery are key unmet needs in this market.

needle icon

The global hospital injectables market is $624.5 billion5

Grey and white globe

313 million surgeries are performed in US each year6

USA icon

There are 1.7 million US hospital-acquired infections leading to 99 thousand deaths annually7

dollar sign icon

Hospital costs in US for critically ill patients have doubled in the past decade to $108 billion8

Our Pipeline

Novel Injectables

Product CandidatesTherapeutic AreaResearchPreclinicalPhase IPhase IIPhase III
NVK009Acute Pain
Research
Preclinical
Phase I
Phase II
Phase III
NVK006Anti-infective
Research
Preclinical
Phase I
Phase II
Phase III
NVK043Novel Injectable
Research
Preclinical
Phase I
Phase II
Phase III

Critical Care Injectables

Product CandidatesTherapeutic AreaResearchPreclinicalPhase IPhase IIPhase III
NVK004Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK003Anesthesia
Research
Preclinical
Phase I
Phase II
Phase III
NVK005Oncology
Research
Preclinical
Phase I
Phase II
Phase III
NVK014CardiovascularApproved
NVK019Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK025Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK028Cardiovascular
Research
Preclinical
Phase I
Phase II
Phase III
NVK030Gastrointestinal
Research
Preclinical
Phase I
Phase II
Phase III
NVK035Critical Care
Research
Preclinical
Phase I
Phase II
Phase III
NVK041Critical Care
Research
Preclinical
Phase I
Phase II
Phase III

References for Hospital Injectables:
5. https://www.marketsandmarkets.com/Market-Reports/injectable-drug-delivery-market-150.html. 6. Gan TJ et al. Curr Med Res Opin. 2014;30(1):149-160 7.https://patientcarelink.org/improving-patient-care/healthcare-acquired-infections-hais/   8. https://www.sccm.org/Communications/Critical-Care-Statistics.